Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia-Reference-Cited by-同舟云学术

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

Published:2011-12 Issue:12 Volume:35 Page:1557-1563
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Gugliotta Luigi,Tieghi Alessia,Tortorella Giovanni,Scalzulli Potito Rosario,Ciancia Rosanna,Lunghi Monia,Cacciola Emma,Cacciola Rossella,Candoni Anna,Crugnola Monica,Codeluppi Katia,Usala Emilio,Specchia Giorgina,Martinelli Vincenzo,Palmieri Fausto,Pierri Ivana,Liberati Anna Marina,Iurlo Alessandra,Grossi Alberto,Vannucchi Alessandro M.,Vianelli Nicola,Mazzucconi Maria Gabriella

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Anagrelide for control of thrombocythemia in polycythemia vera and other myeloproliferative disorders;Petitt;Semin Hematol,1997

2. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders;Fruchtman;Leuk Res,2005

3. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia;Harrison;NEJM,2005

4. Final results of the ANAHYDRET-study: non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO-essential thrombocythemia patients;Gisslinger;Blood,2008

5. Long-term use of anagrelide in young patients with essential thrombocythemia;Storen;Blood,2001

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis;Thrombosis Research;2023-06

2. Anagrelide‐induced pericardial effusion in a patient with essential thrombocythemia;Clinical Case Reports;2023-04

3. Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review;Biomedicines;2023-01-28

4. Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review;Internal Medicine;2022-11-01

5. Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose;International Journal of Hematology;2022-05-27